These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 20053748)

  • 1. Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model.
    Norton EB; Clements JD; Voss TG; Cárdenas-Freytag L
    J Virol; 2010 Mar; 84(6):2983-95. PubMed ID: 20053748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.
    Tumpey TM; Renshaw M; Clements JD; Katz JM
    J Virol; 2001 Jun; 75(11):5141-50. PubMed ID: 11333895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant.
    Choi AH; McNeal MM; Flint JA; Basu M; Lycke NY; Clements JD; Bean JA; Davis HL; McCluskie MJ; VanCott JL; Ward RL
    Vaccine; 2002 Mar; 20(13-14):1733-40. PubMed ID: 11906760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells.
    Guebre-Xabier M; Hammond SA; Epperson DE; Yu J; Ellingsworth L; Glenn GM
    J Virol; 2003 May; 77(9):5218-25. PubMed ID: 12692224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants.
    McCluskie MJ; Weeratna RD; Clements JD; Davis HL
    Vaccine; 2001 Jun; 19(27):3759-68. PubMed ID: 11395211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.
    Tamura S; Yamanaka A; Shimohara M; Tomita T; Komase K; Tsuda Y; Suzuki Y; Nagamine T; Kawahara K; Danbara H
    Vaccine; 1994 Apr; 12(5):419-26. PubMed ID: 8023550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innate imprinting by the modified heat-labile toxin of Escherichia coli (LTK63) provides generic protection against lung infectious disease.
    Williams AE; Edwards L; Humphreys IR; Snelgrove R; Rae A; Rappuoli R; Hussell T
    J Immunol; 2004 Dec; 173(12):7435-43. PubMed ID: 15585869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G).
    Maier M; Seabrook TJ; Lemere CA
    Vaccine; 2005 Oct; 23(44):5149-59. PubMed ID: 16054274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG oligodeoxynucleotides protect against the 2009 H1N1 pandemic influenza virus infection in a murine model.
    Jiang T; Zhao H; Li XF; Deng YQ; Liu J; Xu LJ; Han JF; Cao RY; Qin ED; Qin CF
    Antiviral Res; 2011 Jan; 89(1):124-6. PubMed ID: 21115063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1).
    Matassov D; Cupo A; Galarza JM
    Viral Immunol; 2007 Sep; 20(3):441-52. PubMed ID: 17931114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LTA1 is a safe, intranasal enterotoxin-based adjuvant that improves vaccine protection against influenza in young, old and B-cell-depleted (μMT) mice.
    Valli E; Harriett AJ; Nowakowska MK; Baudier RL; Provosty WB; McSween Z; Lawson LB; Nakanishi Y; Norton EB
    Sci Rep; 2019 Oct; 9(1):15128. PubMed ID: 31641151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
    Tamura SI; Kurata T
    Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B subunits of cholera toxin and thermolabile enterotoxin of Escherichia coli have similar adjuvant effect as whole molecules on rotavirus 2/6-VLP specific antibody responses and induce a Th17-like response after intrarectal immunization.
    Thiam F; Charpilienne A; Poncet D; Kohli E; Basset C
    Microb Pathog; 2015 Dec; 89():27-34. PubMed ID: 26318874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge.
    O'Neal CM; Clements JD; Estes MK; Conner ME
    J Virol; 1998 Apr; 72(4):3390-3. PubMed ID: 9525668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The protective effects of intranasal administration of IL-12 given before influenza virus infection and the negative effects of IL-12 treatment given after viral infection.
    Ishikawa H; Ino S; Sasaki H; Fukui T; Kohda C; Tanaka K
    J Med Virol; 2016 Sep; 88(9):1487-96. PubMed ID: 26864280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae.
    Ryan ET; Crean TI; John M; Butterton JR; Clements JD; Calderwood SB
    Infect Immun; 1999 Apr; 67(4):1694-701. PubMed ID: 10085006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine.
    Lu X; Clements JD; Katz JM
    Vaccine; 2002 Jan; 20(7-8):1019-29. PubMed ID: 11803061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins.
    Connell TD
    Expert Rev Vaccines; 2007 Oct; 6(5):821-34. PubMed ID: 17931161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.
    Boyaka PN; Ohmura M; Fujihashi K; Koga T; Yamamoto M; Kweon MN; Takeda Y; Jackson RJ; Kiyono H; Yuki Y; McGhee JR
    J Immunol; 2003 Jan; 170(1):454-62. PubMed ID: 12496431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged protection against Intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant.
    Zhou F; Goodsell A; Uematsu Y; Vajdy M
    Clin Vaccine Immunol; 2009 Apr; 16(4):471-8. PubMed ID: 19193829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.